assays is a Singapore-based company supported by a joint venture between QIAGEN and Bio*One Capital of Singapore. We develop to specification for client provided targets.
ASSAY DEVELOPMENT FOR PHARMACEUTICAL INDUSTRY
Robust assays with comprehensive analytical validation enable better pre-clinical development and internal decision-making. Development can be customized for use in lead optimization and toxicology.
ASSAY DEVELOPMENT FOR MOLECULAR DIAGNOSTICS
Diagnostic assays are required to facilitate the replacement of conventional “one fits all” approaches with tailored treatment, thus enabling physician’s decision-making process taking into account genetic predisposition and exact characterization of the disease.
Drug makers are becoming increasingly aware of the need for MDx when tailoring drug development to biomarker-defined patient populations. However, their core competency often differs from diagnostic test development. Dx assays assists by designing and developing companion diagnostics to specification in a timely manner.
|
